

Published in final edited form as:


J Org Chem. 2006 November 10; 71(23): 8891–8900. doi:10.1021/jo061660a.

Synthetic Studies on Perphoramidine and the Communesins: Construction of the Vicinal Quaternary Stereocenters

Jae Hong Seo, Gerald D. Artman III, and Steven M. Weinreb

Department of Chemistry, The Pennsylvania State University University Park, Pennsylvania 16802

Abstract



An efficient synthetic strategy for installation of the two vicinal quaternary carbon centers of the communesins is reported. Key steps include the O-allylation/Claisen rearrangement of spirocyclic systems, which are formed by tandem intramolecular Heck cyclization/carbonylation. Substituent and solvent effects on the stereochemical outcome of the Claisen rearrangements have been examined. The stereochemical assignment of the allyl spirolactone previously reported as **17** has now been revised to **32**, which has the communesin relative configuration at the quaternary carbons. Key C-allyl spirolactone **59** bearing functional handles required for the communesin core has been constructed with a 9.8:1 diastereomer ratio.

Introduction and Background

About a decade ago, Numata, et al. reported two unusual natural products isolated from a *Penicillium* mold found growing on the marine alga *Enteromorpha intestinalis*.¹ The unique structures of these two compounds, communesin A (**1**) and communesin B (**5**), were established by spectroscopic analysis (Figure 1). An interesting feature of these complex, highly functionalized polycyclic compounds is the two contiguous quaternary centers at C-7,8. Communesins A and B were found to have *in vitro* cytotoxic activity against P-388 lymphoid leukemia cells. In 2001, Hemscheidt and coworkers described a metabolite called nomofungin, which was isolated from an unidentified fungus growing on the bark of *Ficus microcarpa* in Hawaii.² This material was found to have cytotoxic activity against LoVo and KB cells, which was shown to be due to the ability of the metabolite to cause microfilament disruption. The metabolite was initially proposed to have structure **9**, but it was later found that this assignment

E-mail: smw@chem.psu.edu.

Supporting Information Available

 Copies of proton and carbon NMR spectra of new compounds along with X-ray data for compounds **30** and **32**. This material is available free of charge on the Internet at <http://pubs.acs.org>.

was in error, and that nomofungin is actually communesin B (**5**). It should be noted, however, that the Hemscheidt work did serve to establish both the configuration at C-21 of **5** as well as the absolute configuration of the molecule, which were not originally determined by the Numata group. Recently, several other modified communesin derivatives have been isolated³ including communesin C (**6**),⁴ D (**7**), E (**2**), F (**8**), G (**3**) and H (**4**) (Figure 1). Some of these new compounds were found to have significant biological activity. For example, communesins D, E and F are insecticidal,^{3b} and communesins C and D are moderately active against various leukemia cell lines.^{3a}

In 2002, Ireland reported the isolation of a congeneric compound, perphoramidine, from the marine ascidian *Perophora namei* collected in the Philippines.⁵ Based mainly upon NMR spectral analysis, this metabolite was assigned the hexacyclic structure **10**, which contains some unique features including two amidine units, two chlorines and a bromine. Like the communesins, perphoramidine has two adjacent quaternary carbons at C-4,20, but interestingly, the natural products have the opposite relative stereochemistry at these centers. Perphoramidine has cytotoxicity against the HCT116 colon carcinoma cell line, and also induces apoptosis via PARP cleavage.

Perphoramidine and the communesins have closely related structures and presumably arise via a common biogenetic pathway.⁶ Some model studies on biogenetically-patterned synthesis of the communesin/perphoramidine ring system by the Stoltz,⁷ and Qin⁸ groups have appeared, as well as a model hetero Diels-Alder-based approach by Crawley and Funk.⁹ Moreover, Fuchs and Funk have completed an elegant, biogenetically-inspired total synthesis of racemic perphoramidine.¹⁰ In addition, Rainier and coworkers recently described a nice total synthesis of dehaloperphoramidine.¹¹

In 2003, we disclosed some preliminary results on a Heck-based strategy for total synthesis of these alkaloids.¹² In this work, it was found that acrylamides **11** and **12** underwent tandem intramolecular Heck cyclization/carbonylation¹³ to afford E/F-lactam esters **13** and **14**, respectively, in good yields (Scheme 1). These compounds could then be cleanly cyclized to lactones **15** and **16** after removal of the TBS protecting groups. As part of these studies, we reported that lactone **16** could be deprotonated and alkylated with allyl bromide to afford a single product to which we assigned the perphoramidine relative stereochemistry at the quaternary centers as shown in **17** via ¹H NMR NOESY experiments. Based upon the subsequent studies discussed in this paper, we have found that the configurational assignment of this alkylation product is in fact incorrect (*vide infra*).

Results and Discussion

Because we believed that we had been able to efficiently access the requisite perphoramidine C-4,20 quaternary carbon stereochemistry, work was undertaken on synthesis of a Heck substrate bearing the appropriate C-ring substituents. Using a two-step procedure developed by Coe¹⁴ heating commercially available 4-bromo-2-nitrotoluene (**18**) in the presence of *N,N*-dimethylformamide dimethyl acetal and pyrrolidine in DMF generated the known enamine **19**.¹⁵ which was oxidatively cleaved using NaIO₄ in THF/H₂O to afford the desired benzaldehyde **20** in 93 % yield over two steps (Scheme 2). Wittig olefination of the aldehyde **20** with readily available ylide **21**¹⁶ in refluxing toluene generated the benzylidene lactone **22** in excellent yield. Ring opening of this unsaturated lactone with the aluminium amide reagent¹⁷ derived from the commercially available aniline **23** produced the nitro acrylamide **24** in quantitative yield. Subsequent protection of the primary alcohol moiety of **24** as its TBS ether and alkylation of the amide nitrogen using NaH/MOMCl resulted in the *N*-MOM acrylamide **25** in 84 % yield over the two steps.

To continue the synthesis, the Heck reaction/carbonylation sequence with substrate **25** was examined, leading to the desired lactam ester **28** as a mixture of diastereomers along with the reductive Heck product **27**¹⁸ and ester **26** derived from uncyclized starting iodide (Scheme 3). The ratios of these products varied widely depending upon the specific reaction conditions (Pd source, ligand, solvent, base, etc) used for the Heck/carbonylation step. However, the formation of the desired cyclization products **28** was optimal under the conditions shown in the scheme. Although compounds **26-28** could be separated by chromatography and characterized spectrally (see Experimental Section), it was found best to simply expose the crude reaction mixture to TBAF, leading to lactone **29** (4:1 diastereomeric mixture) in 51% isolated overall yield from substrate **25**.

This mixture of lactones was deprotonated with sodium hydride in DMF at room temperature, upon which allyl iodide was added, and the mixture was heated in an oil bath at 90 °C. This reaction produced a single crystalline alkylation product in excellent yield whose structure was established unambiguously by X-ray analysis. We were quite surprised to find, however, that the allylated lactone has the communesin stereochemistry shown in **30** rather than the expected perophoramidine configuration at the quaternary centers.

In view of this unexpected stereochemical result, we decided to reexamine the model system shown in Scheme 1.¹² Thus, the lactone product from C-allylation of **16**¹⁹ was exposed to the reagent derived from ammonium chloride and trimethylaluminum²⁰ to afford hydroxy amide **32** (Scheme 4). This material provided crystals suitable for X-ray analysis, which established that the allylation product of **16** in fact has the communesin stereochemistry shown in **31**, and is not the perophoramidine diastereomer **17** which had originally been assigned.

Since the experiments outlined above suggested that we might be able to access the quaternary carbons of the communesins stereoselectively, we turned to an investigation of systems bearing useful C and F aromatic ring substituents for synthesis of this group of metabolites. Using methodology similar to that described above, Heck substrate **33** was prepared in a few steps. It was found, however, that under most conditions, the Heck/carbonylation sequence led to the reduced compound **35** as the major or sole product rather than the desired ester **34** (Scheme 5). After substantial experimentation, it was possible at best to produce equal amounts of **34** and **35** along with a small quantity of ester **36** using the conditions shown in the scheme. It should be noted that a similar tendency for intramolecular reductive Heck reactions has been observed by Denmark and Schnute when using nitroolefins.^{18a} The rationale presented for these results would also apply to our cases involving nitroarenes **25** and **33**. Since the desired transformation of Heck substrate **33** to ester **34** was not synthetically useful, we turned to an alternative system lacking the nitro group which was expected to be more amenable to the requisite Heck/carbonylation process.

One solution we considered was to install the required C-ring nitrogen via a late-stage Curtius rearrangement of a system bearing a suitable carbon substituent. Thus, Heck substrate **43** was constructed via the chemistry outlined in Scheme 6. Known benzyl alcohol **37**²¹ was first converted to the benzyl ether **38**, and the nitro group was subsequently reduced to afford aniline **39**. Conversion of this amine to the corresponding aluminum amide¹⁷ followed by reaction with benzylidene lactone **40**²² then led to amide **41** in high yield. The alcohol functionality of **41** was protected as the TBS ether **42**, and the amide nitrogen was methylated to yield the desired substrate **43**. This compound underwent smooth tandem Heck cyclization/carbonylation to produce the desired lactam ester **44** as a single stereoisomer whose configuration was not proven, but by analogy with **13/14**¹² is assumed to be as shown.

Treatment of silyl ether ester **44** with TBAF led to desilylation and *in situ* cyclization to lactone **45**, which was produced as a 2:1 mixture of diastereomers (Scheme 7). During work with

spirolactone **45** it was discovered that allylation of the corresponding enolate does not actually involve a direct C-alkylation. Thus, treatment of **45** with sodium hydride in DMF along with allyl iodide at room temperature affords the chromatographically isolable ketene acetal **46** in 57% yield (71% based on recovered lactone, formed via hydrolysis of **46** during purification). Ketene acetal **46** appears to exist as a 2:1 mixture of atropisomers, as can be seen by ^1H NMR. It was found that heating ketene acetal **46** at 130 °C in either DMF or toluene led to a Claisen rearrangement producing a separable mixture of diastereomeric C-allylation products **47** and **48**, with a slightly better stereoselectivity in the former solvent. The stereochemistry of the minor isomer was established by ^1H NMR NOESY analysis to have the configuration shown in **48** (see Supporting Information). It should be noted that although we cannot isolate the ketene acetals in the two alkylations described above, we believe these processes also involve an initial O-allylation followed by a Claisen rearrangement (*vide infra*).

In view of the disappointing level of stereoselectivity in the alkylation of lactone **45**, we decided to explore an alternative system with different substitution in the F-ring with the hope of improving this key step. Known, easily prepared phenol **49**²³ was therefore first converted to the carbamate **50** and the nitro group was reduced to yield the aniline **51** (Scheme 8). Condensation of this intermediate with benzylidene lactone **40** then produced amide **52** in excellent overall yield. The alcohol functionality of **52** was protected as the MOM ether **53**, and the amide nitrogen was methylated to afford **54**. The tandem Heck cyclization/ carbonylation of this substrate proceeded cleanly to generate the requisite lactam ester **55** as a single stereoisomer assumed to be as indicated.

The MOM protecting group of **55** was next removed with methanolic HCl to give the desired spirolactone **57** along with some of the uncyclized hydroxy ester **56** (Scheme 9). O-Allylation of the spirolactone as was done with **45** gave the ketene acetal **58**, which in this case was again a 2:1 mixture of atropisomers. Heating **58** in DMF at 110°C did not show improved stereoselectivity over the system in Scheme 7, leading to a 2.3:1 mixture of stereoisomers **59** and **60** in good yield. We have been unable to definitively establish the configurations of these diastereomers, but by analogy with the three cases described above we believe the major isomer has the communesin configuration shown in **59**. We were pleased to find, however, that heating ketene acetal **58** in toluene induced a Claisen rearrangement, which led to a synthetically useful 9.8:1 mixture of **59:60**.

To rationalize the high stereoselectivity shown in the first two lactone allylations (cf. Schemes 3 and 4), we considered four possible half-chair transition state conformations for the Claisen rearrangement of the corresponding ketene acetal intermediates (Figure 2). The carbonyl group of the oxy-indole moiety (EF rings) could occupy either pseudo-axial (**A**) or pseudo-equatorial (**E**) positions. In addition, each transition state has two possible atropisomers (α and β) derived from the position of the substituent (**R**) at C(10) in the C-ring aryl moiety. It seems reasonable that the allyl group approaches the ketene acetal double bond from the face opposite to this substituent in order to avoid severe steric interactions.²⁴ Since axial attack of the allyl group is more favorable stereoelectronically,²⁵ transition states **A- β** and **E- α** are expected to be preferable to conformations **A- α** and **E- β** . In addition, it appears from inspection of models that the aryl group of the oxy-indole moiety blocks attack of the allyl substituent more effectively than does the carbonyl group, and therefore transition state **E- α** would seem to be favored over **A- β** . Steric interactions and/or electronic repulsions between the carbonyl group and the substituent **R** (OMe or NO₂) may additionally destabilize conformation **A- β** .

On the other hand, allylation of the lactones bearing substituents (**R''**) at the C-12a position of the oxy-indole moiety showed lower stereoselectivity than did the above two cases (cf. Schemes 7 and 9). As shown in Figure 3, substituent **R''** causes substantial steric interactions not only with substituent **R** in **E- α** but also with the allyl group in **A- β** . As noted above, NMR

analysis shows that there is little preference for one atropisomer in ketene acetals **46** and **58** at room temperature. These steric interactions presumably slow the Claisen rearrangements of the latter two ketene acetals, making these species more easily isolable, and also lead to generally low stereoselectivities. At this point, however, we are unable to explain why we observe high stereoselectivity in the rearrangement of ketene acetal **58** in toluene.

In conclusion, we have developed a concise strategy to construct systems bearing the two quaternary centers of the communesins. Key steps in this approach involve an intramolecular tandem Heck cyclization/carbonylation, followed by a stereoselective O-allylation/Claisen rearrangement of a spirolactone enolate. We are currently attempting to utilize this methodology in a total synthesis of the communesins.

Experimental Section

3-(4-Bromo-2-nitrophenyl)-2-[2-(*tert*-butyldimethylsilyloxy)ethyl]-*N*-(2,4-dichloro-6-iodophenyl)-*N*-methoxymethylacrylamide (**25**)

N,N-Dimethylformamide dimethyl acetal (7.25 mL, 54.6 mmol) and pyrrolidine (4.50 mL, 53.9 mmol) were added to 4-bromo-2-nitrotoluene (**18**, 9.66 g, 44.7 mmol, TCI) in DMF (25 mL). The reaction mixture was heated at 110 °C for 4 h to give a dark red solution. The reaction mixture was cooled to rt and the volatile organics were removed under reduced pressure resulting in the known enamine **19**¹⁵ as a mass of red crystals.

The above enamine was dissolved in THF (30 mL) and added slowly to NaIO₄ (28.9 g, 135 mmol) in 50% aqueous THF (200 mL) while maintaining the temperature below 20 °C. The reaction mixture was rapidly stirred for an additional 2 h and the insoluble salts were removed by filtration and washed with EtOAc. The combined organic filtrate was washed with water, dried (MgSO₄) and concentrated. The crude product was purified by flash silica gel chromatography (1:9 EtOAc: hexanes) to afford the desired 4-bromo-2-nitrobenzaldehyde (**20**, 9.58 g, 93%) as a yellow solid (mp 93-95 °C; lit. mp 95 °C²⁶). IR (KBr) 3085, 2912, 2863, 1812, 1691, 1525 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 10.38 (d, *J* = 0.6 Hz, 1H), 8.26 (d, *J* = 1.7 Hz, 1H), 7.93 (ddd, *J* = 8.3, 1.8, 0.6 Hz, 1H), 7.84 (d, *J* = 8.3 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 187.2, 150.1, 137.4, 131.1, 129.9, 128.4, 127.8.

3-(Triphenyl-λ⁵-phosphanylidene)dihydrofuran-2-one (**21**, 4.62 g, 13.3 mmol)¹⁶ was added to nitrobenzaldehyde **20** (3.07 g, 13.3 mmol) in toluene (70 mL). The reaction mixture was heated at reflux for 2 h and cooled to rt. The volatile organics were removed under reduced pressure. The crude product was absorbed onto silica gel and purified by flash silica gel column chromatography (1:2 EtOAc: hexanes) to afford the benzylidene lactone **22** (3.96 g, 100%) as a light brown solid (mp 129-131 °C). IR (KBr) 2929, 2867, 1762, 1523 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.25 (d, *J* = 1.8 Hz, 1H), 7.82 (dd, *J* = 8.3, 1.8 Hz, 1H), 7.78 (t, *J* = 2.9 Hz, 1H), 7.42 (d, *J* = 8.3 Hz, 1H), 4.46 (t, *J* = 7.2 Hz, 2H), 3.07 (dd, *J* = 7.2, 3.0 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 170.8, 148.8, 136.7, 131.3, 129.3, 129.0, 128.4, 123.5, 65.7, 26.9.

2,4-Dichloro-6-iodoaniline (**23**, 11.1 g, 39 mmol, TCI) was dissolved in benzene (60 mL) and slowly added via syringe to AlMe₃ (2.0 M in hexanes, 21 mL, 42 mmol) in benzene (10 mL) at 0 °C. After stirring the mixture for an additional 45 min, the benzylidene lactone **22** (10.4 g, 35 mmol) dissolved in CH₂Cl₂ (60 mL) was slowly added via syringe. The reaction mixture was heated at 65 °C for 15 h then cooled to 0 °C. 1 N HCl (50 mL) was slowly added dropwise and the reaction mixture was stirred for an additional 30 min. The organic layer was removed and the aqueous layer was extracted with EtOAc. The combined organic extracts were dried over MgSO₄ and concentrated *in vacuo*. The crude oil was absorbed onto silica gel and purified by flash silica gel chromatography (1:2 EtOAc:hexanes) to afford the bromo dichloro acrylamide **24** (16.5 g, 81%) as a foam. ¹H NMR (300 MHz, CDCl₃) δ 8.33 (d, *J* = 2.0 Hz,

1H), 8.05 (s, 1H), 7.80-7.83 (m, 2H), 7.67 (s, 1H), 7.49 (d, $J = 2.2$ Hz, 1H), 7.43 (d, $J = 8.2$ Hz, 1H), 3.73-3.80 (br m, 2H), 2.63 (t, $J = 5.8$ Hz, 2H), 2.48 (br s, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 167.9, 148.2, 137.6, 137.3, 137.0, 135.1, 134.8, 133.2, 132.8, 132.4, 130.3, 128.4, 122.8, 100.2, 61.5, 31.4.

TBSCl (5.11 g, 33.9 mmol) was added in a single portion to acrylamide **24** (16.3 g, 27.8 mmol) and imidazole (4.20 g, 61.7 mmol) in DMF (30 mL) and the mixture was stirred at rt for 60 min. Water was added and the aqueous phase was extracted with ether. The combined organic extracts were dried over MgSO_4 and concentrated under reduced pressure to afford the desired TBS ether (19.5 g, 100%) as an oil, which was used without further purification. ^1H NMR (400 MHz, CDCl_3) δ 8.56 (s, 1H), 8.28 (d, $J = 2.0$ Hz, 1H), 7.74-7.77 (m, 2H), 7.70 (s, 1H), 7.54 (d, $J = 8.2$ Hz, 1H), 7.45 (d, $J = 2.2$ Hz, 1H), 3.75 (t, $J = 5.6$ Hz, 2H), 2.67 (t, $J = 5.6$ Hz, 2H), 0.82 (s, 9H), 0.02 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 167.3, 148.4, 137.9, 137.7, 136.9, 135.9, 134.7, 133.6, 133.4, 132.8, 130.7, 130.4, 128.4, 122.7, 100.8, 62.8, 31.8, 26.3, 18.7, -5.0; HRMS-APCI: $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{23}\text{H}_{26}\text{BrCl}_2\text{IN}_2\text{O}_4\text{Si}$ 698.9340; found, 698.9366.

NaH (60 % dispersion in mineral oil, 1.33 g, 33.2 mmol) was added to the TBS ether (19.5 g, 27.8 mmol) in THF (140 mL) at 0 °C. The solution was stirred for an additional 20 min at this temperature before MOMCl (3.10 mL, 41.6 mmol) was introduced. The reaction solution was warmed to rt and stirred for 12 h. Saturated aqueous NaHCO_3 (100 mL) was slowly added and the organic layer was removed. The aqueous phase was extracted with EtOAc. The combined organic extracts were dried (MgSO_4) and concentrated under reduced pressure. The crude product was purified by flash silica gel column chromatography (1:4 EtOAc: hexanes) to afford the *N*-MOM amide **25** (17.4 g, 84%) as an oil, which solidified upon standing. ^1H NMR (400 MHz, CDCl_3) δ 8.32 (m, 1H), 7.87 (d, $J = 2.1$ Hz, 1H), 7.75-7.78 (m, 2H), 7.65 (s, 1H), 7.54 (d, $J = 2.1$ Hz, 1H), 5.10 (ABq, $J = 67.1, 10.5$ Hz, 2H), 3.81-3.85 (m, 2H), 3.28 (s, 3H), 2.71 (br. m, 2H), 0.92 (s, 9H), 0.08 (s, 3H), 0.07 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 179.4, 150.8, 137.4, 135.6, 135.1, 133.8, 130.7, 129.3, 128.9, 128.1, 123.3, 121.8, 116.9, 72.0, 59.5, 56.6, 52.8, 40.2, 39.6, 26.1, -5.4; HRMS-APCI: $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{25}\text{H}_{30}\text{BrCl}_2\text{IN}_2\text{O}_5\text{Si}$ 742.9602; found, 742.9572.

(4-Bromo-2-nitrophenyl)-{3-[2-(tert-butylidimethylsilanyloxy)-ethyl]-5,7-dichloro-1-methoxymethyl-2-oxo-2,3-dihydro-1*H*-indol-3-yl}-acetic Acid Methyl Ester (**28**)

To a solution of *N*-MOM amide **25** (27.4 mg, 0.037 mmol) in DMA (2.0 mL) and MeOH (0.4 mL) were added $\text{Pd}_2(\text{dba})_3$ (3.4 mg, 0.004 mmol), $\text{P}(o\text{-Tol})_3$ (4.5 mg, 0.015 mmol), *n*- Bu_4NBr (23.7 mg, 0.074 mmol) and NEt_3 (26 μL , 0.187 mmol). The mixture was stirred at 85 °C under a CO atmosphere (1 atm) for 21 h. The catalyst was removed by filtration and washed with EtOAc. The filtrate was washed with water and brine, dried over Na_2SO_4 and concentrated *in vacuo*. The crude mixture was used for the next step without further purification. For analytical purposes the compounds were separated by preparative TLC (1:5 EtOAc:hexanes). More polar major diastereomer of **28** (pale yellow oil): IR (film) 2946, 2860, 1735, 1536, 1461, 1095 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 8.05 (d, $J = 2.1$ Hz, 1H), 7.70 (dd, $J = 8.5, 2.1$ Hz, 1H), 7.45 (d, $J = 8.5$ Hz, 1H), 7.27 (d, $J = 2.0$ Hz, 1H), 6.76 (d, $J = 2.0$ Hz, 1H), 5.37, 5.30 (ABq, $J = 10.5$ Hz, 2H), 5.09 (s, 1H), 3.65 (s, 3H), 3.42 (s, 3H), 3.24 (td, $J = 6.2, 2.6$ Hz, 2H), 2.25 (td, $J = 6.2, 3.7$ Hz, 2H), 0.72 (s, 9H), -0.17 (d, $J = 2.4$ Hz, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 178.4, 170.2, 151.3, 138.3, 135.6, 133.5, 133.0, 130.9, 128.5, 128.4, 126.8, 124.0, 123.2, 117.2, 72.6, 59.4, 57.1, 53.1, 52.8, 50.4, 37.2, 26.1, 18.6, -5.3, -5.4; HRMS-ES: $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{27}\text{H}_{34}\text{BrCl}_2\text{N}_2\text{O}_7\text{Si}$ 675.0696; found, 675.0712. Less polar minor diastereomer of **28** (pale yellow oil): IR (film) 2946, 2860, 1735, 1536, 1461 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.97 (d, $J = 2.1$ Hz, 1H), 7.56 (dd, $J = 8.5, 2.1$ Hz, 1H), 7.47 (d, $J = 2.0$ Hz, 1H), 7.36 (d, $J = 8.5$ Hz, 1H), 7.30 (d, $J = 2.0$ Hz, 1H), 5.24, 5.19 (ABq, $J = 10.5$ Hz, 2H), 5.16 (s, 1H), 3.64 (s, 3H), 3.29 (t, $J = 6.2$ Hz, 2H), 3.22 (s, 3H), 2.22-2.12 (m, 2H), 0.72 (s,

9H), -0.17 (d, $J = 2.2$ Hz, 6H); ^{13}C NMR (75 MHz, CDCl_3) δ 178.6, 170.4, 151.4, 138.3, 135.7, 133.7, 133.5, 131.2, 129.0, 128.1, 127.0, 124.3, 123.0, 116.9, 72.3, 59.3, 56.8, 53.3, 53.2, 51.0, 39.3, 26.1, 18.6, -5.3 , -5.4 ; HRMS-ES: $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{27}\text{H}_{34}\text{BrCl}_2\text{N}_2\text{O}_7\text{Si}$ 675.0696; found, 675.0672.

3-(4-Bromo-2-nitrobenzyl)-3-[2-(tert-butyldimethylsilyloxy)-ethyl]-5,7-dichloro-1-methoxymethyl-1,3-dihydroindol-2-one (27)

Pale yellow oil. IR (film) 2935, 2860, 1730, 1536, 1461, 1348 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.83 (d, $J = 2.0$ Hz, 1H), 7.52 (dd, $J = 8.3, 2.0$ Hz, 1H), 7.21 (d, $J = 2.0$ Hz, 1H), 7.12 (d, $J = 8.3$ Hz, 1H), 6.99 (d, $J = 2.0$ Hz, 1H), 5.19 (s, 2H), 3.80, 3.41 (ABq, $J = 13.7$ Hz, 2H), 3.37 (m, 2H), 3.32 (s, 3H), 2.32 (dt, $J = 13.8, 6.9$ Hz, 1H), 2.08 (dt, $J = 13.8, 5.5$ Hz, 1H), 0.75 (s, 9H), -0.14 (d, $J = 3.4$ Hz, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 179.4, 150.8, 137.3, 135.7, 135.1, 133.8, 130.6, 129.3, 128.9, 128.1, 123.4, 121.8, 116.9, 72.0, 59.5, 56.5, 52.8, 40.3, 39.6, 26.1, 18.5, -5.36 , -5.37 ; HRMS-ES: $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{25}\text{H}_{32}\text{BrCl}_2\text{N}_2\text{O}_5\text{Si}$ 617.0641; found, 617.0659.

2-[[2-(4-Bromo-2-nitrobenzylidene)-4-(tert-butyldimethylsilyloxy)-butyryl]-methoxymethylamino]-3,5-dichlorobenzoic Acid Methyl Ester (26)

Yellow solid (mp 125-126 °C). IR (film) 2946, 2860, 1730, 1665, 1531, 1278 cm^{-1} ; ^1H NMR (360 MHz, CDCl_3 , 5:1 atropisomer mixture) δ 8.30 (d, $J = 1.8$ Hz, 1H, *major*), 8.09 (d, $J = 1.7$ Hz, 1H, *minor*), 7.89 (d, $J = 2.4$ Hz, 1H, *major*), 7.85 (d, $J = 2.4$ Hz, 1H, *minor*), 7.77 (d, $J = 1.8$ Hz, 1H, *minor*), 7.75-7.69 (m, 3H, *major*), 7.67 (m, 1H, *minor*), 7.46 (s, 1H, *major*), 7.22 (d, $J = 8.2$ Hz, 1H, *minor*), 7.00 (s, 1H, *minor*), 5.23, 4.85 (ABq, $J = 10.5$ Hz, 2H, *minor*), 5.20, 4.79 (ABq, $J = 10.2$ Hz, 2H, *major*), 3.92 (s, 3H, *minor*), 3.89 (s, 3H, *major*), 3.84 (t, $J = 6.0$ Hz, 2H, *major*), 3.74 (m, 2H, *minor*), 3.46 (s, 3H, *minor*), 3.21 (s, 3H, *major*), 2.68 (m, 2H, *major*), 2.41 (m, 2H, *minor*), 0.90 (s, 9H, *major*), 0.83 (s, 9H, *minor*), 0.07 (s, 6H, *major*), -0.02 (s, 6H, *minor*); ^{13}C NMR (75 MHz, CDCl_3) δ 171.7, 164.7, 148.5, 137.6, 136.6, 136.4, 136.2, 134.9, 134.1, 133.8, 133.1, 130.9, 130.5, 129.4, 128.2, 122.4, 83.3, 61.0, 56.8, 53.3, 33.4, 26.3, 18.7, -5.0 ; HRMS-ES: $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{27}\text{H}_{34}\text{BrCl}_2\text{N}_2\text{O}_7\text{Si}$ 675.0696; found, 675.0665.

Synthesis of Spirolactone 29

To a stirred solution of the above crude mixture of Heck/carbonylation adducts in THF (3.0 mL) was added TBAF (0.072 mL, 1.0 M in THF, 0.072 mmol) at 0 °C. The reaction mixture was warmed to rt and stirred overnight. The mixture was diluted with EtOAc and saturated aqueous NH_4Cl . The organic layer was dried over Na_2SO_4 and concentrated *in vacuo*. The residue was purified by flash column chromatography (1:4 EtOAc:hexanes) to give the spiro lactone **29** (9.9 mg, 51% over 2 steps) as a pale yellow oil. IR (film) 2924, 1725, 1531, 1455, 1348 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3 , 4:1 diastereomeric mixture) δ 7.95 (s, 1H, *minor*), 7.79 (d, $J = 1.9$ Hz, 1H, *major*), 7.61 (dd, $J = 8.5, 1.9$ Hz, 1H, *major*), 7.45 (dd, $J = 8.6, 1.8$ Hz, 1H, *minor*), 7.41 (d, $J = 8.5$ Hz, 1H, *major*), 7.34 (s, 1H, *minor*), 7.25 (d, $J = 1.8$ Hz, 1H, *major*), 7.22 (s, 1H, *minor*), 7.12 (d, $J = 1.7$ Hz, 1H, *major*), 6.68 (d, $J = 8.5$ Hz, 1H, *minor*), 5.50 (br s, 1H, *minor*), 5.44 (s, 1H, *major*), 5.30 (s, 1H, *minor*), 5.21, 5.18 (ABq, $J = 10.3$ Hz, 2H, *major*), 5.13 (s, 1H, *minor*), 5.06 (dt, $J = 11.5, 4.2$ Hz, 1H, *major*), 4.85 (m, 1H, *minor*), 4.72 (m, 1H, *minor*), 4.64 (dt, $J = 11.7, 4.7$ Hz, 1H, *major*), 3.23 (s, 3H, *major*), 2.99 (s, 3H, *minor*), 2.59-2.52 (m, 1H, *major* and *minor*), 2.26 (m, 1H, *minor*), 2.19 (dt, $J = 14.6, 4.0$ Hz, 1H, *major*); ^{13}C NMR (75 MHz, CDCl_3) δ 177.4, 168.8, 150.6, 136.3, 136.2, 134.5, 132.5, 131.8, 130.5, 127.9, 126.6, 123.1, 122.7, 117.6, 72.0, 65.2, 56.8, 52.7, 46.8, 33.2; HRMS-ES: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{20}\text{H}_{15}\text{BrCl}_2\text{N}_2\text{NaO}_6$ 550.9388; found, 550.9388.

Allylation of Spirolactone 29

To a stirred suspension of spiro lactone **29** (102 mg, 0.191 mmol) and NaH (9.2 mg, 60% dispersion in mineral oil, 0.230 mmol) in DMF (2.0 mL) was added allyl iodide (0.026 mL, 0.287 mmol) at 0 °C. The mixture was stirred at rt for 1 h and heated at 90 °C for 7 h. The reaction mixture was cooled to rt, diluted with saturated aqueous NH₄Cl and extracted with EtOAc. The organic layer was washed with water and brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash column chromatography (1:2 EtOAc:hexanes) to give the allyl lactone **30** (95 mg, 87%) as a yellow solid (mp 157-158 °C). Recrystallization from EtOAc provided X-ray quality crystals of **30**. IR (film) 2924, 1725, 1536, 1461, 1359 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.81 (d, *J* = 2.0 Hz, 1H), 7.33 (dd, *J* = 8.6, 2.0 Hz, 1H), 7.10 (d, *J* = 1.9 Hz, 1H), 6.81 (d, *J* = 1.8 Hz, 1H), 6.68 (d, *J* = 8.7 Hz, 1H), 5.51-5.34 (m, 4H), 4.99 (d, *J* = 17.2 Hz, 1H), 4.94 (d, *J* = 10.4 Hz, 1H), 4.61 (dt, *J* = 11.6, 4.0 Hz, 1H), 3.44 (s, 3H), 3.35 (dd, *J* = 15.2, 6.3 Hz, 1H), 2.99 (ddd, *J* = 15.2, 10.9, 4.3 Hz, 1H), 2.86 (dd, *J* = 15.4, 7.1 Hz, 1H), 2.16 (dt, *J* = 14.7, 3.0 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 178.3, 168.0, 150.8, 136.1, 134.8, 134.3, 132.7, 132.6, 132.4, 131.1, 129.0, 128.0, 125.1, 122.1, 120.3, 116.9, 72.3, 65.0, 57.1, 54.4, 54.2, 44.1, 31.5; HRMS-ES: [M+Na]⁺ calcd for C₂₃H₁₉BrCl₂N₂NaO₆ 590.9701; found, 590.9697.

2-[5,7-Dichloro-3-(2-hydroxyethyl)-1-methoxymethyl-2-oxo-2,3-dihydro-1*H*-indol-3-yl]-2-(2-methoxyphenyl)-pent-4-enoic Acid Amide (**32**)

To a stirred suspension of NH₄Cl (229 mg, 4.28 mmol) in toluene (5 mL) was slowly added Me₃Al (2.30 mL, 2.0 M in hexanes, 4.60 mmol) at 0 °C. After the addition was complete, the reaction mixture was allowed to warm to rt and was stirred for 1.5 h. To a solution of lactone **31** (291 mg, 0.61 mmol) in toluene (15 mL) was added the above aluminum amide reagent at rt, and the mixture was heated at 80 °C overnight. The reaction mixture was cooled to rt and was carefully quenched with 1N HCl. The organic layer was separated and the aqueous layer was extracted with CH₂Cl₂. The combined organic layers were dried over MgSO₄ and concentrated *in vacuo*. The residue was purified by flash column chromatography (10:10:1 CH₂Cl₂:EtOAc:MeOH) to give the amide **32** (286 mg, 95%) as a yellow solid (mp 179-180 °C). Recrystallization from EtOAc provided X-ray quality crystals of **32**. IR (film) 3342, 1708, 1672, 1461 cm⁻¹; ¹H NMR (300 MHz, CDCl₃+CD₃OD) δ 7.85 (br s, 1H), 7.14 (t, *J* = 7.7 Hz, 1H), 7.06 (d, *J* = 1.6 Hz, 1H), 6.78 (t, *J* = 7.6 Hz, 1H), 6.54 (br s, 1H), 5.87 (m, 1H), 5.51 (br s, 1H), 5.17 (d, *J* = 16.8 Hz, 1H), 5.03 (d, *J* = 10.0 Hz, 1H), 4.65 (br s, 2H), 3.55-2.89 (m, 10H), 2.42 (br s, 1H); ¹³C NMR (75 MHz, CDCl₃+CD₃OD) δ 180.2, 174.7, 156.9, 136.9, 134.6, 134.0, 131.1, 129.6, 129.1, 128.2, 127.3, 124.7, 119.4, 118.4, 114.6, 110.7, 71.3, 58.8, 58.4, 57.0, 56.3, 54.1, 37.3, 34.7; HRMS-ES: [M+H]⁺ calcd for C₂₄H₂₇Cl₂N₂O₅ 493.1297; found, 493.1285.

1-Benzyloxymethyl-2-iodo-3-nitrobenzene (**38**)

To a stirred solution of (2-iodo-3-nitrophenyl)-methanol (**37**)²¹ (0.86 g, 3.08 mmol) in CH₂Cl₂ (6 mL) and cyclohexane (10 mL) was added benzyl 2,2,2-trichloroacetimidate (1.14 mL, 6.13 mmol), followed by TfOH (0.03 mL, 0.34 mmol). The mixture was stirred at rt for 9 h and then diluted with saturated aqueous NaHCO₃ and EtOAc. The organic layer was dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash column chromatography (1:15 EtOAc:hexanes) to give benzyl ether **38** (1.06 g, 93%) as a yellow oil. IR (film) 2871, 1712, 1526, 1350 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.72 (d, *J* = 7.6 Hz, 1H), 7.58 (dd, *J* = 7.9, 1.4 Hz, 1H), 7.48 (t, *J* = 7.8 Hz, 1H), 7.44-7.32 (m, 5H), 4.71 (s, 2H), 4.63 (s, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 144.6, 137.9, 131.6, 129.4, 129.0, 128.4, 128.2, 123.9, 89.1, 76.9, 73.5; HRMS-EI: [M]⁺ calcd for C₁₄H₁₂INO₃ 368.9862; found, 368.9866.

3-Benzyloxymethyl-2-iodophenylamine (39)

To a solution of the nitrobenzene **38** (1.05 g, 2.83 mmol) in EtOH (10 mL) and glacial acetic acid (10 mL) was added iron powder (0.79 g, 14.15 mmol). The mixture was heated at 60 °C for 3 h and then cooled to rt. The mixture was diluted with iced water and carefully neutralized with solid Na₂CO₃. The resulting solution was extracted with EtOAc. The combined organic layers were dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash column chromatography (1:5 EtOAc:hexanes) to give the aniline **39** (0.83 g, 97%) as a colorless oil. IR (film) 3447, 3357, 2859, 1610, 1463 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.45–7.29 (m, 5H), 7.14 (t, *J* = 7.7 Hz, 1H), 6.89 (d, *J* = 6.9 Hz, 1H), 6.72 (dd, *J* = 7.9, 0.9 Hz, 1H), 4.65 (s, 2H), 4.56 (s, 2H), 4.00 (bs, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 147.4, 141.8, 138.6, 129.2, 128.9, 128.3, 128.1, 119.4, 114.5, 88.6, 77.2, 73.0; HRMS-ES: [M+H]⁺ calcd for C₁₄H₁₅INO 340.0198; found, 340.0195.

N-(3-Benzyloxymethyl-2-iodophenyl)-4-hydroxy-2-[2-(4-methoxyphenoxy)methyl]-benzylidene]-butyramide (41)

To a stirred solution of the aniline **39** (0.69 g, 2.03 mmol) and lactone **40**²² (0.57 g, 1.84 mmol) in CH₂Cl₂ (30 mL) was added AlMe₃ (1.80 mL, 2.0 M in hexane, 3.60 mmol) at 0 °C. The mixture was warmed to rt, stirred overnight and then poured into ice cold aqueous NH₄Cl. The aqueous layer was extracted with CH₂Cl₂. The organic layer was dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash column chromatography (1:1 EtOAc:hexanes) to give the amide **41** (1.16 g, 97%) as a white solid (mp 126.5–127 °C). IR (film) 3368, 2859, 1661, 1509, 1226 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 8.35 (s, 1H), 8.11 (dd, *J* = 8.0, 1.5 Hz, 1H), 7.68 (s, 1H), 7.54 (m, 1H), 7.51–7.28 (m, 10H), 6.94–6.89 (m, 2H), 6.84–6.80 (m, 2H), 5.03 (s, 2H), 4.64 (s, 2H), 4.55 (s, 2H), 3.79 (t, *J* = 5.8 Hz, 2H), 3.74 (s, 3H), 2.77 (t, *J* = 5.8 Hz, 2H), 2.70 (br s, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 168.9, 154.6, 153.1, 141.9, 138.64, 138.61, 138.3, 135.5, 135.3, 134.3, 129.9, 129.6, 129.3, 129.00, 128.95, 128.9, 128.3, 125.9, 122.5, 116.3, 115.2, 96.0, 77.1, 73.1, 69.7, 62.5, 56.2, 31.9; HRMS-ES: [M+H]⁺ calcd for C₃₃H₃₃INO₅ 650.1404; found, 650.1404.

N-(3-Benzyloxymethyl-2-iodophenyl)-4-(tert-butyldimethylsilyloxy)-2-[2-(4-methoxyphenoxy)methyl]-benzylidene]-butyramide (42)

To a solution of the amide **41** (568 mg, 0.87 mmol) and imidazole (178 mg, 2.62 mmol) in DMF (8.7 mL) was added TBSCl (316 mg, 2.09 mmol). The reaction mixture was stirred at rt overnight and then diluted with EtOAc. The solution was washed with water and brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash column chromatography (1:3 EtOAc:hexanes) to give the TBS ether **42** (641 mg, 96%) as a colorless oil. IR (film) 2950, 2848, 1678, 1509, 1226, 1090 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.44 (s, 1H), 8.2 (dd, *J* = 8.0, 1.4 Hz, 1H), 7.74 (s, 1H), 7.56 (m, 1H), 7.44–7.29 (m, 9H), 6.94–6.91 (m, 2H), 6.85–6.82 (m, 2H), 5.03 (s, 2H), 4.65 (s, 2H), 4.59 (s, 2H), 3.9 (t, *J* = 6.1 Hz, 2H), 3.76 (s, 3H), 2.84 (t, *J* = 6.1 Hz, 2H), 0.87 (s, 9H), 0.03 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 167.7, 154.5, 153.3, 141.8, 139.0, 138.5, 138.3, 135.7, 135.2, 134.1, 129.9, 129.3, 129.2, 128.9, 128.8, 128.5, 128.23, 128.21, 125.6, 122.4, 116.4, 115.1, 95.9, 77.2, 73.1, 69.4, 62.5, 56.1, 31.8, 26.4, 18.8, -4.9; HRMS-ES: [M+H]⁺ calcd for C₃₉H₄₇INO₅Si 764.2268; found, 764.2271.

N-(3-Benzyloxymethyl-2-iodophenyl)-4-(tert-butyldimethylsilyloxy)-2-[2-(4-methoxyphenoxy)methyl]-benzylidene]-*N*-methylbutyramide (43)

To a stirred suspension of NaH (40 mg, 60% dispersion in mineral oil, 1.01 mmol) in THF (8 mL) was added a solution of the amide **42** (641 mg, 0.84 mmol) in THF (3 mL) at 0 °C. The mixture was stirred at rt for 30 min and recooled to 0 °C. To the solution was added MeI (0.08 mL, 1.29 mmol) and the reaction mixture was warmed to rt and stirred for 12 h. The reaction

mixture was diluted with saturated aqueous NH_4Cl and extracted with EtOAc. The organic layer was dried over Na_2SO_4 and concentrated *in vacuo*. The residue was purified by flash column chromatography (1:3 EtOAc:hexanes) to give the *N*-methyl amide **43** (630 mg, 96%) as a colorless oil. IR (film) 2950, 2860, 1650, 1509, 1226, 1090 cm^{-1} ; ^1H NMR (300 MHz, toluene- d_8 , 90 °C) δ 7.38 (m, 1H), 7.28–7.01 (m, 12H), 6.78 (dt, $J = 12.8, 3.8$ Hz, 2H), 6.72 (dt, $J = 12.8, 3.8$ Hz, 2H), 4.59 (d, $J = 5.5$ Hz, 2H), 4.42 (d, $J = 7.1$ Hz, 2H), 4.38 (s, 2H), 3.94 (m, 2H), 3.45 (s, 3H), 3.22 (s, 3H), 2.75 (m, 1H), 2.57 (m, 1H), 0.95 (s, 9H), 0.07 (s, 6H); ^{13}C NMR (75 MHz, toluene- d_8 , 90 °C) δ 170.7, 155.1, 153.6, 148.3, 144.3, 137.5, 129.2, 136.3, 135.1, 131.9, 129.2, 129.1, 128.7, 128.5, 128.1, 127.84, 127.78, 127.7, 127.53, 127.48, 116.9, 115.3, 103.3, 77.1, 73.1, 69.1, 62.5, 55.4, 37.6, 34.0, 26.2, 18.5, –5.2; HRMS-ES: $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{40}\text{H}_{49}\text{INO}_5\text{Si}$ 778.2425; found, 778.2397.

{4-Benzoyloxymethyl-3-[2-(tert-butylidimethylsilyloxy)-ethyl]-1-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl}-[2-(4-methoxyphenoxyethyl)-phenyl]-acetic Acid Methyl Ester (**44**)

To a solution of *N*-methyl amide **43** (222 mg, 0.286 mmol) in DMA (3.0 mL) and MeOH (1.5 mL) were added $\text{Pd}(\text{OAc})_2$ (6.4 mg, 0.029 mmol), biphenyldicyclohexylphosphine (30.1 mg, 0.086 mmol) and NaOAc (46.9 mg, 0.572 mmol). The mixture was stirred at 85 °C under a CO atmosphere (1 atm) for 24 h. The catalyst was removed by filtration and washed with EtOAc. The filtrate was washed with water and brine, dried over Na_2SO_4 and concentrated *in vacuo*. The residue was purified by flash column chromatography (1:5 EtOAc:hexanes) to give the methyl ester **44** (145 mg, 71%) as a colorless oil. IR (film) 2950, 2859, 1740, 1712, 1509, 1226 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.35–7.17 (m, 9H), 7.12 (dd, $J = 14.8, 7.5$ Hz, 1H), 7.07 (d, $J = 7.9$ Hz, 1H), 6.87 (d, $J = 9.1$ Hz, 2H), 6.82 (d, $J = 9.2$ Hz, 2H), 6.65 (d, $J = 7.7$ Hz, 1H), 4.93, 4.69 (ABq, $J = 11.6$ Hz, 2H), 4.63 (s, 1H), 4.41, 4.29 (ABq, $J = 11.9$ Hz, 2H), 3.89, 3.77 (ABq, $J = 11.1$ Hz, 2H), 3.78 (s, 3H), 3.59 (s, 3H), 3.19 (m, 2H), 3.10 (s, 3H), 2.56 (dt, $J = 14.4, 7.2$ Hz, 1H), 2.13 (dt, $J = 13.4, 4.9$ Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 178.2, 171.6, 154.5, 153.1, 145.4, 138.2, 136.5, 136.0, 133.4, 130.6, 129.7, 129.0, 128.8, 128.4, 128.3, 128.2, 128.1, 126.1, 123.5, 116.2, 115.1, 107.6, 73.4, 69.2, 68.9, 60.0, 56.1, 55.1, 52.5, 38.0, 26.9, 26.4, 26.2, 18.6, –5.3, –5.4; HRMS-ES: $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{42}\text{H}_{52}\text{NO}_7\text{Si}$ 710.3513; found, 710.3521.

Synthesis of Spirolactone **45**

To a stirred solution of methyl ester **44** (172 mg, 0.24 mmol) in THF (10 mL) was added TBAF (0.27 mL, 1.0 M in THF, 0.27 mmol) at 0 °C. The reaction mixture was warmed to rt and stirred for 4 h. The mixture was diluted with EtOAc and saturated aqueous NH_4Cl . The organic layer was dried over Na_2SO_4 and concentrated *in vacuo*. The residue was purified by flash column chromatography (1:1 EtOAc:hexanes) to give the lactone **45** (116 mg, 85%) as a separable mixture of diastereomers (2:1). For analytical purposes the diastereomers were separated by preparative TLC (1:1 EtOAc:hexanes). More polar major diastereomer of **45** (colorless oil): IR (film) 2927, 1752, 1712, 1605, 1509, 1226 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 7.38–7.01 (m, 11H), 6.83–6.74 (m, 4H), 6.54 (d, $J = 7.7$ Hz, 1H), 5.03 (s, 1H), 4.83 (ddd, $J = 11.7, 6.7, 4.9$ Hz, 1H), 4.67–4.43 (m, 6H), 4.30 (ddd, $J = 11.8, 7.2, 4.6$ Hz, 1H), 3.77 (s, 3H), 2.96 (s, 3H), 2.61 (ddd, $J = 14.7, 6.8, 4.8$ Hz, 1H), 2.27 (ddd, $J = 14.6, 7.4, 5.1$ Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 178.2, 171.1, 154.5, 153.0, 144.1, 137.3, 136.5, 134.4, 132.3, 130.8, 129.7, 129.2, 129.1, 128.79, 128.75, 128.7, 128.2, 127.8, 125.1, 116.3, 115.1, 108.6, 73.8, 70.0, 69.7, 64.8, 56.2, 52.6, 47.2, 30.3, 26.5; HRMS-ES: $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{35}\text{H}_{34}\text{NO}_6$ 564.2386; found, 564.2391. Less polar minor diastereomer of **45** (colorless oil): IR (film) 2916, 1746, 1706, 1610, 1509, 1232 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.44–7.30 (m, 5H), 7.27–7.23 (m, 3H), 7.09 (t, $J = 7.6$ Hz, 1H), 6.93 (d, $J = 9.0$ Hz, 2H), 6.88–6.84 (m, 3H), 6.63 (d, $J = 7.8$ Hz, 1H), 6.54 (d, $J = 7.4$ Hz, 1H), 5.32 (d, $J = 11.7$ Hz, 1H), 4.98 (s, 1H), 4.80–4.55 (m, 6H), 4.38 (dd, $J = 11.7, 5.6$ Hz, 1H), 3.79 (s, 3H), 2.91 (s, 3H), 2.73 (td, $J = 14.5, 5.8$ Hz, 1H), 2.23 (d, $J = 14.9$ Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 179.4, 172.6, 154.6, 153.1, 144.2, 138.2, 136.7,

136.0, 131.5, 130.8, 129.8, 129.7, 129.0, 128.9, 128.6, 128.3, 128.2, 127.5, 125.4, 116.6, 115.1, 108.5, 73.6, 70.2, 69.2, 66.1, 56.1, 52.5, 47.1, 31.6, 26.8; HRMS-ES: $[M+Na]^+$ calcd for $C_{35}H_{33}NNaO_6$ 586.2206; found, 586.2210.

O-Allylation of Spirolactone 45

To a stirred suspension of spirolactone **45** (20.6 mg, 0.037 mmol) and NaH (2.0 mg, 60% dispersion in mineral oil, 0.050 mmol) in DMF (2 mL) was added allyl iodide (0.010 mL, 0.109 mmol) at 0 °C. The mixture was stirred for 1 h at rt. The reaction mixture was diluted with saturated aqueous NH_4Cl and extracted with EtOAc. The organic layer was washed with water and brine, dried over Na_2SO_4 and concentrated *in vacuo*. The residue was purified by flash column chromatography (1:2 EtOAc:hexanes) to give the *O*-allyl ketene acetal **46** (12.7 mg, 57%, 71% based on recovered starting material) as a colorless oil, and unreacted spirolactone **45** (3.9 mg). IR (film) 3470, 2927, 1706, 1509, 1226 cm^{-1} ; 1H NMR (400 MHz, $CDCl_3$, 2:1 atropisomeric mixture) δ 7.44–7.22 (m, 7H, *major and minor*), 7.13 (t, $J = 7.7$ Hz, 1H, *minor*), 7.08–7.01 (m, 1H, *major and minor*), 6.98–6.96 (m, 2H, *major and minor*), 6.91 (d, $J = 6.7$ Hz, 1H, *minor*), 6.86–6.82 (m, 3H, *major and minor*), 6.77 (t, $J = 7.6$ Hz, 1H, *major*), 6.58 (d, $J = 8.1$ Hz, 1H, *major and minor*), 6.35 (d, $J = 7.8$ Hz, 1H, *minor*), 5.78 (m, 1H, *major and minor*), 5.27 (d, $J = 13.3$ Hz, 1H, *major*), 5.17–5.06 (m, 3H, *major, 2H, minor*), 5.01–4.84 (m, 2H, *major and minor*), 4.77–4.65 (m, 2H, *major, 3H, minor*), 4.44–4.24 (m, 4H, *major and minor*), 3.78 (s, 3H, *major and minor*), 3.16 (s, 3H, *minor*), 2.95 (s, 3H, *major*), 2.58 (m, 1H, *major and minor*), 1.98 (d, $J = 14.6$ Hz, 1H, *major*), 1.85 (d, $J = 14.3$ Hz, 1H, *minor*). ^{13}C NMR (300 MHz, $CDCl_3$) δ 180.7, 179.4, 157.6, 156.3, 154.0, 153.9, 153.8, 153.6, 144.0, 143.6, 138.32, 138.27, 137.2, 135.2, 134.7, 134.0, 133.7, 133.4, 132.7, 130.9, 130.2, 129.8, 129.6, 129.0, 128.9, 128.81, 128.76, 128.4, 128.34, 128.26, 128.1, 127.5, 127.4, 127.1, 127.0, 126.7, 126.4, 125.2, 124.4, 118.22, 118.16, 116.2, 115.9, 115.0, 114.9, 108.0, 107.9, 87.1, 84.4, 73.8, 73.5, 69.30, 69.26, 68.33, 68.26, 65.5, 64.6, 56.1, 50.5, 50.4, 32.6, 31.4, 26.8, 26.6; HRMS-ES: $[M+H]^+$ calcd for $C_{38}H_{37}NO_6$ 604.2699; found, 604.2684.

Thermal Claisen Rearrangement of Ketene Acetal 46

A solution of ketene acetal **46** in DMF or toluene was heated at 130 °C and stirred for 15 h. The solvent was removed under reduced pressure. The residue was purified by preparative TLC (1:1 EtOAc:hexanes) to give the two allyl lactone diastereomers **47** and **48**. More polar major diastereomer **47** (oil): IR (film) 2929, 1704, 1508, 1228 cm^{-1} ; 1H NMR (300 MHz, toluene- d_8 , 90 °C) δ 7.56 (d, $J = 7.9$ Hz, 1H), 7.26–6.98 (m, 9H), 6.90 (t, $J = 7.2$ Hz, 1H), 6.80–6.67 (m, 4H), 6.38 (d, $J = 6.8$ Hz, 1H), 6.10 (m, 1H), 5.21 (br. s, 1H), 5.13 (td, $J = 12.1$, 4.4 Hz, 1H), 4.77 (s, 1H), 4.72 (d, $J = 8.8$ Hz, 1H), 4.52 (br. s, 1H), 4.20, 4.13 (ABq, $J = 12.1$ Hz, 2H), 4.06 (dd, $J = 11.0$, 7.0 Hz, 1H), 3.47 (s, 3H), 3.16 (m, 1H), 3.15 (s, 2H), 2.85 (m, 1H), 2.81 (s, 3H), 2.53 (dd, $J = 15.4$, 6.8 Hz, 1H), 1.35 (dd, $J = 14.7$, 4.6 Hz, 1H); ^{13}C NMR (75 MHz, toluene- d_8 , 90 °C) δ 176.5, 172.4, 155.3, 154.0, 145.1, 139.6, 139.1, 138.6, 137.8, 137.3, 134.1, 132.3, 129.4, 128.7, 128.2, 127.9, 127.5, 126.7, 127.5, 126.7, 125.8, 116.1, 115.7, 107.5, 73.0, 69.6, 69.0, 64.6, 59.1, 57.0, 55.7, 41.2, 27.2, 25.7; HRMS-ES: $[M+H]^+$ calcd for $C_{38}H_{38}NO_6$ 604.2699; found, 604.2714. Less polar *minor* diastereomer **48** (oil): IR (film) 2918, 1704, 1508, 1228 cm^{-1} ; 1H NMR (300 MHz, toluene- d_8 , 90 °C) δ 7.83 (d, $J = 7.6$ Hz, 1H), 7.29 (d, $J = 7.6$ Hz, 2H), 7.22–6.96 (m, 8H), 6.77 (d, $J = 8.8$ Hz, 2H), 6.60 (t, $J = 7.8$ Hz, 1H), 6.36 (br s, 1H), 5.99 (d, $J = 7.7$ Hz, 1H), 5.77 (m, 1H), 5.52 (td, $J = 12.3$, 4.1 Hz, 1H), 5.33 (d, $J = 11.8$ Hz, 1H), 4.98–4.85 (m, 3H), 4.60, 4.57 (ABq, $J = 10.3$ Hz, 2H), 4.50, 4.44 (ABq, $J = 11.9$ Hz, 2H), 4.0 (dd, $J = 11.1$, 6.9 Hz, 1H), 3.47 (s, 3H), 3.39 (dd, $J = 14.7$, 5.6 Hz, 1H), 2.95 (dd, $J = 14.3$, 6.7 Hz, 1H), 2.74 (td, $J = 14.4$, 6.9 Hz, 1H), 2.32 (s, 3H), 1.42 (dd, $J = 14.7$, 3.7 Hz, 1H); ^{13}C NMR (75 MHz, toluene- d_8 , 90 °C) δ 177.2, 169.9, 155.1, 154.8, 145.9, 139.7, 138.1, 137.4, 137.2, 134.5, 133.9, 129.5, 129.4, 129.3, 128.9, 128.4, 127.5, 127.3, 125.9, 125.6, 117.7, 117.1, 115.6, 107.8, 73.6, 71.2, 70.4, 64.7, 57.9, 57.8, 55.7, 42.0, 26.9, 25.4; HRMS-ES: $[M+H]^+$ calcd for $C_{38}H_{38}NO_6$ 604.2699; found, 604.2722.

Dimethylcarbamic Acid 2-Iodo-3-nitrophenyl Ester (50)

To a stirred solution of 2-iodo-3-nitrophenol (**49**, 422 mg, 1.59 mmol), NEt₃ (0.33 mL, 2.35 mmol)²³ and DMAP (19.4 mg, 0.16 mmol) in CH₂Cl₂ (20 mL) was added *N,N*-dimethylcarbonyl chloride (0.18 mL, 1.96 mmol) at 0 °C. The mixture was warmed to rt and stirred overnight. The reaction mixture was diluted with CH₂Cl₂, washed with water and brine, dried over MgSO₄ and concentrated *in vacuo*. The crude residue was purified by flash column chromatography (1:1 EtOAc:hexanes) to give the carbamoyl-protected phenol **50** (505 mg, 94%) as a white solid (mp 125-126 °C). IR (film) 1713, 1531, 1386, 1359, 1246, 1165 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.75 (dd, *J* = 7.9, 1.4 Hz, 1H), 7.60 (t, *J* = 8.0 Hz, 1H), 7.53 (dd, *J* = 8.1, 1.4 Hz, 1H), 3.35 (s, 3H), 3.19 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 155.1, 153.9, 153.4, 130.0, 127.3, 122.4, 86.1, 37.5, 37.3; HRMS-ES: [M+Na]⁺ calcd for C₉H₉IN₂NaO₄ 358.9505; found, 358.9513.

Dimethylcarbamic Acid 3-Amino-2-iodophenyl Ester (51)

To a solution of the nitrobenzene **50** (446 mg, 1.33 mmol) in EtOH (10 mL) and glacial acetic acid (5 mL) was added iron powder (296 mg, 5.30 mmol). The mixture was heated at 60 °C for 4 h and then cooled to rt. The mixture was diluted with water and carefully neutralized with solid Na₂CO₃. The resulting solution was extracted with EtOAc. The combined organic layers were dried over MgSO₄ and concentrated *in vacuo*. The residue was purified by flash column chromatography (1:1 EtOAc:hexanes) to give the aniline **51** (375 mg, 93%) as a white solid (mp 113-114 °C). IR (film) 3333, 1714, 1617, 1466, 1386, 1170 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.33 (t, *J* = 7.9 Hz, 1H), 6.80 (dd, *J* = 8.0, 2.9 Hz, 2H), 4.50 (br s, 2H), 3.42 (s, 3H), 3.28 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 154.3, 152.7, 149.0, 129.8, 113.0, 112.2, 82.0, 37.3, 37.2; HRMS-ES: [M+H]⁺ calcd for C₉H₁₂IN₂O₂ 306.9944; found, 306.9949.

Dimethylcarbamic Acid 3-{4-Hydroxy-2-[2-(4-methoxyphenoxy)methyl]benzylidene}butyrylamino-2-iodophenyl Ester (52)

To a stirred solution of aniline **51** (111 mg, 0.362 mmol) and lactone **40**²² (107 mg, 0.345 mmol) in CH₂Cl₂ (10 mL) was added AlMe₃ (0.19 mL, 2.0 M in hexane, 0.380 mmol) at 0 °C. The mixture was warmed to rt, stirred overnight and then carefully diluted with saturated aqueous NH₄Cl at 0 °C, followed by CH₂Cl₂. The organic layer was washed with water, dried over MgSO₄ and concentrated *in vacuo*. The residue was purified by flash column chromatography (10:1 CH₂Cl₂:MeOH) to give the amide **52** (207 mg, 97%) as a white solid (mp 110-111 °C). IR (film) 3387, 2934, 1725, 1665, 1509, 1229 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 8.37 (s, 1H), 8.06 (dd, *J* = 8.2, 1.4 Hz, 1H), 7.64 (s, 1H), 7.53-7.51 (m, 1H), 7.40-7.31 (m, 4H), 6.97 (dd, *J* = 8.1, 1.4 Hz, 1H), 6.92-6.79 (m, 4H), 5.01 (s, 2H), 3.75 (t, *J* = 5.9 Hz, 2H), 3.74 (s, 3H), 3.18 (s, 3H), 3.03 (s, 3H), 2.74 (t, *J* = 5.8 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 168.7, 154.6, 154.0, 153.2, 152.4, 140.0, 138.5, 135.6, 135.2, 134.5, 129.9, 129.7, 129.6, 129.0, 128.8, 119.82, 119.76, 116.4, 115.2, 89.4, 69.6, 62.3, 56.2, 37.3, 37.2, 31.8; HRMS-ES: [M+H]⁺ calcd for C₂₈H₃₀IN₂O₆ 617.1149; found, 617.1139.

Dimethylcarbamic Acid 2-Iodo-3-{4-methoxymethoxy-2-[2-(4-methoxyphenoxy)methyl]benzylidene}butyrylamino}phenyl Ester (53)

To a mixture of amide **52** (961 mg, 1.56 mmol), (*i*-Pr)₂NEt (0.54 mL, 3.10 mmol) and NaI (467 mg, 3.12 mmol) in CH₂Cl₂ (30 mL) was added MOMCl (0.18 mL, 2.37 mmol) at 0 °C. The mixture was warmed to rt, stirred overnight and then diluted with saturated aqueous NaHCO₃ and CH₂Cl₂. The organic layer was dried over MgSO₄ and concentrated *in vacuo*. The residue was purified by flash column chromatography (1:1 EtOAc:hexanes) to give the MOM ether **53** (914 mg, 89%) as a white solid (mp 107-108 °C). IR (film) 3389, 2937, 1729, 1673, 1509, 1385, 1232 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 8.32 (s, 1H), 8.17 (dd, *J* = 8.3, 1.3 Hz, 1H), 7.67 (s, 1H), 7.57-7.54 (m, 1H), 7.43-7.34 (m, 4H), 6.98 (dd, *J* = 8.3, 1.3 Hz,

1H), 6.93-6.80 (m, 4H), 5.02 (s, 2H), 4.58 (s, 2H), 3.75 (s, 3H), 3.70 (t, $J = 6.3$ Hz, 2H), 3.29 (s, 3H), 3.19 (s, 3H), 3.05 (s, 3H), 2.84 (t, $J = 6.3$ Hz, 2H); ^{13}C NMR (75 MHz, CDCl_3) δ 167.6, 154.6, 153.9, 153.2, 152.3, 140.2, 138.1, 135.8, 135.1, 134.4, 130.0, 129.5, 129.3, 128.9, 128.6, 119.5, 119.4, 116.4, 115.2, 96.7, 88.8, 69.4, 66.5, 56.2, 55.8, 37.3, 37.2, 29.0; HRMS-ES: $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{30}\text{H}_{34}\text{N}_2\text{O}_7$ 661.1411; found, 661.1397.

Dimethylcarbamic Acid 2-Iodo-3-((4-methoxymethoxy-2-[2-(4-methoxyphenoxy)methyl]benzylidene]butyryl)methylamino)phenyl Ester (54)

To a stirred suspension of NaH (11.1 mg, 60% dispersion in mineral oil, 0.278 mmol) in THF (6 mL) was added a solution of lactam **53** (167 mg, 0.253 mmol) in THF (4 mL) at 0 °C. The mixture was stirred at rt for 1 h and recooled to 0 °C. To the solution was added MeI (0.019 mL, 0.305 mmol) and the reaction mixture was warmed to rt and stirred overnight. The reaction mixture was diluted with saturated aqueous NH_4Cl and water and extracted with CH_2Cl_2 . The organic layer was dried over MgSO_4 and concentrated *in vacuo*. The residue was purified by flash column chromatography (10:10:1 CH_2Cl_2 :EtOAc:MeOH) to give the *N*-methyl amide **54** (167 mg, 98%) as a colorless oil. IR (film) 2926, 1723, 1616, 1503, 1227, 1164 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 7.38–6.96 (m, 8H), 6.81 (br s, 4H), 4.68–4.48 (m, 4H), 3.77 (s, 3H), 3.67 (br s, 2H), 3.36 (s, 6H), 3.11 (s, 3H), 3.02 (s, 3H), 2.59 (br s, 1H), 2.43 (br s, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 171.6, 154.4, 153.8, 153.1, 148.8, 136.5, 135.9, 134.4, 133.2, 130.2, 129.1, 128.4, 127.8, 127.0, 122.8, 116.5, 114.9, 97.3, 96.6, 68.5, 66.2, 56.1, 55.7, 37.8, 37.3, 37.1, 30.3; HRMS-ES: $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{31}\text{H}_{36}\text{N}_2\text{O}_7$ 675.1567; found, 675.1562.

[4-Dimethylcarbamoyloxy-3-(2-methoxymethoxyethyl)-1-methyl-2-oxo-2,3-dihydro-1*H*-indol-3-yl]-[2-(4-methoxyphenoxy)methyl]phenyl]acetic Acid Methyl Ester (55)

To a solution of *N*-methyl amide **54** (280 mg, 0.415 mmol) in DMA (2.6 mL) and MeOH (1.3 mL) were added $\text{Pd}(\text{OAc})_2$ (18.6 mg, 0.083 mmol), $\text{P}(o\text{-Tol})_3$ (75.7 mg, 0.249 mmol) and NaOAc (68.0 mg, 0.829 mmol). The mixture was stirred at 90 °C under a CO atmosphere (1 atm) for 1 d. The reaction mixture was cooled to rt and diluted with EtOAc. The solution was washed with water and brine, dried over MgSO_4 and concentrated *in vacuo*. The residue was purified by flash column chromatography (1:2 EtOAc:hexanes) to give the ester **55** (199 mg, 79%) as a colorless oil. IR (film) 2938, 1729, 1616, 1509, 1226 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 7.53–7.50 (m, 1H), 7.32–7.16 (m, 4H), 6.97 (d, $J = 8.4$ Hz, 1H), 6.88–6.80 (m, 4H), 6.51 (d, $J = 7.6$ Hz, 1H), 5.08, 4.85 (ABq, $J = 11.6$ Hz, 2H), 4.68 (s, 1H), 4.32, 4.21 (ABq, $J = 6.5$ Hz, 2H), 3.78 (s, 3H), 3.61 (s, 3H), 3.19–3.03 (m, 2H), 3.12 (s, 3H), 3.09 (s, 3H), 2.88 (s, 3H), 2.64 (s, 3H), 2.63–2.55 (m, 1H), 2.47–2.40 (m, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 177.9, 171.2, 154.5, 153.4, 153.1, 148.7, 146.3, 136.5, 133.5, 130.6, 129.9, 129.6, 128.3, 127.9, 118.6, 116.8, 116.3, 115.0, 104.9, 96.7, 69.2, 64.4, 56.2, 55.4, 54.5, 52.6, 37.2, 36.4, 34.2, 26.9; HRMS-ES: $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{33}\text{H}_{39}\text{N}_2\text{O}_9$ 607.2656; found, 607.2645.

Synthesis of Spirolactone 57

To a stirred solution of ester **55** (61.1 mg, 0.101 mmol) in MeOH (5.0 mL) was added concentrated HCl (1 drop) at rt. The mixture was warmed to 60 °C and stirred for 4 h. The solvent was removed under reduced pressure and the residue was purified by flash column chromatography (3:1 EtOAc:hexanes) to give spiro lactone **57** (37.5 mg, 70%) as a white solid (mp 213–215 °C) and hydroxy ester **56** (9.5 mg, 17%) as a colorless oil. Spiro lactone **57**: IR (film) 1729, 1712, 1622, 1509, 1226, 1158 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 7.47 (dd, $J = 7.5, 1.1$ Hz, 1H), 7.27–7.19 (m, 2H), 7.12 (td, $J = 7.6, 1.3$ Hz, 1H), 7.04 (dd, $J = 7.6, 1.4$ Hz, 1H), 6.82 (dd, $J = 8.4, 0.6$ Hz, 1H), 6.78–6.70 (m, 4H), 6.42 (d, $J = 7.8$ Hz, 1H), 5.01 (ddd, $J = 11.4, 6.8, 4.7$ Hz, 1H), 4.97 (s, 1H), 4.94 (d, $J = 11.9$ Hz, 1H), 4.56 (ddd, $J = 11.7, 7.5, 4.2$ Hz, 1H), 4.50 (d, $J = 11.9$ Hz, 1H), 3.75 (s, 3H), 3.00 (s, 3H), 2.95 (s, 3H), 2.94 (s, 3H), 2.55 (ddd, $J = 14.8, 6.7, 4.4$ Hz, 1H), 2.42 (ddd, $J = 14.7, 7.7, 4.7$ Hz, 1H); ^{13}C NMR (75 MHz,

CDCl₃) δ 177.5, 170.8, 154.6, 154.3, 152.9, 148.2, 144.9, 136.5, 132.2, 131.4, 130.6, 129.5, 128.3, 128.0, 121.9, 118.0, 116.7, 115.0, 106.0, 69.8, 65.0, 56.1, 52.1, 46.6, 37.6, 36.8, 30.4, 26.7; HRMS-ES: [M+Na]⁺ calcd for C₃₀H₃₀N₂NaO₇ 553.1951; found, 553.1963.

Hydroxy ester **56**: IR (film) 3470, 2927, 1735, 1712, 1616, 1509, 1226, 1152 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.54–7.52 (m, 1H), 7.28–7.17 (m, 4H), 6.86–6.80 (m, 5H), 6.53 (d, *J* = 7.7 Hz, 1H), 5.07, 4.83 (ABq, *J* = 12.9 Hz, 2H), 4.70 (s, 1H), 3.78 (s, 3H), 3.64 (s, 3H), 3.34 (t, *J* = 6.3 Hz, 2H), 3.12 (s, 3H), 2.92 (s, 3H), 2.72 (s, 3H), 2.56 (dt, *J* = 13.8, 6.9 Hz, 1H), 2.34 (dt, *J* = 12.7, 6.4 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 177.9, 171.2, 154.5, 154.4, 153.0, 148.3, 146.2, 136.4, 133.4, 130.6, 130.0, 129.6, 128.2, 128.0, 120.3, 117.2, 116.2, 115.0, 105.5, 69.2, 59.6, 56.2, 54.6, 52.7, 37.4, 37.2, 36.6, 27.0; HRMS-ES: [M+H]⁺ calcd for C₃₁H₃₅N₂O₈ 563.2393; found, 563.2392.

O-Allylation of Spirolactone **57**

To a stirred suspension of spirolactone **57** (69.1 mg, 0.130 mmol) and NaH (6.2 mg, 60% dispersion in mineral oil, 0.155 mmol) in DMF (2 mL) was added allyl iodide (0.024 mL, 0.262 mmol) at rt. The mixture was stirred at rt overnight. The reaction mixture was diluted with saturated aqueous NH₄Cl and extracted with EtOAc. The organic layer was washed with water and brine, dried over MgSO₄ and concentrated *in vacuo*. The residue was purified by flash column chromatography (1:1 EtOAc:hexanes) to give the *O*-allyl ketene acetal **58** (46.6 mg, 63%) as a colorless oil. IR (film) 2916, 1712, 1616, 1509, 1226 cm⁻¹; ¹H NMR (300 MHz, CDCl₃, 2:1 atropisomeric mixture) δ 7.40 (d, *J* = 7.3 Hz, 1H), 7.26–6.95 (m, 7.5H), 6.90–6.77 (m, 4.5 H), 6.73 (s, 2H), 6.46 (d, *J* = 7.7 Hz, 1H), 6.43 (d, *J* = 7.8 Hz, 0.5H), 5.80–5.64 (m, 1.5H), 5.24–4.86 (m, 7.5H), 4.38–4.27 (m, 4.5H), 3.78 (s, 3H), 3.76 (s, 1.5H), 3.18 (s, 3H), 3.76 (s, 1.5H), 3.18 (s, 3H), 3.073 (s, 3H), 3.067 (s, 3H), 2.99 (s, 1.5H), 2.95 (s, 3H), 2.49–2.39 (m, 1.5H), 2.08–1.99 (m, 1.5H); ¹³C NMR (75 MHz, CDCl₃) δ 180.0, 179.0, 157.1, 156.2, 154.5, 154.3, 153.9, 153.8, 153.5, 148.2, 148.0, 145.1, 145.0, 138.6, 138.1, 134.0, 133.7, 132.9, 132.5, 131.5, 131.1, 129.6, 129.5, 127.5, 127.2, 126.7, 126.4, 126.2, 123.0, 122.5, 118.3, 118.2, 117.9, 117.7, 116.3, 116.2, 115.0, 114.8, 105.5, 105.3, 88.0, 84.6, 69.5, 69.4, 68.5, 68.3, 65.1, 65.0, 56.2, 50.20, 50.15, 37.5, 37.4, 36.9, 31.6, 29.8, 26.9, 26.8; HRMS-ES: [M+H]⁺ calcd for C₃₃H₃₅N₂O₇ 571.2444; found, 571.2429.

Claisen Rearrangement of Ketene Acetal **58**

A solution of ketene acetal **58** in DMF or toluene was heated at 110 °C and stirred overnight. The solvent was removed under reduced pressure. The residue was purified by flash column chromatography (1:1 EtOAc:hexanes) to give the allyl lactone diastereomers **59** and **60**. More polar major diastereomer **59** (pale yellow oil): IR (film) 2927, 1729, 1712, 1616, 1502, 1226, 1158 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.46 (br s, 1H), 7.23 (t, *J* = 8.0 Hz, 2H), 7.17 (t, *J* = 7.0 Hz, 1H), 6.83 (d, *J* = 8.7 Hz, 2H), 6.77 (br s, 2H), 6.60–6.56 (m, 2H), 5.64 (m, 1H), 5.04–4.87 (m, 3H), 4.66 (br s, 1H), 4.47 (br s, 1H), 3.79 (s, 3H), 3.22 (br s, 1H), 3.10 (s, 3H), 2.92–2.87 (m, 4H), 2.78–2.70 (m, 4H), 2.29 (m, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 175.8, 171.9, 154.0, 153.7, 153.0, 149.3, 145.0, 137.0, 134.9, 134.3, 131.7, 131.4, 130.1, 127.5, 126.8, 120.1, 118.3, 116.9, 115.0, 114.5, 105.2, 68.7, 65.4, 55.7, 55.4, 38.4, 36.9, 36.5, 29.7, 29.4, 24.6; HRMS-ES: [M+Na]⁺ calcd for C₃₃H₃₄N₂NaO₇ 593.2264; found, 593.2263. Less polar *minor* diastereomer **60** (pale yellow oil): IR (film) 2927, 1729, 1712, 1616, 1509, 1226, 1164 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.71 (br s, 1H), 7.30 (t, *J* = 8.1 Hz, 2H), 7.17 (t, *J* = 7.5 Hz, 1H), 7.02–7.00 (m, 2H), 6.90–6.83 (m, 4H), 6.54 (br s, 1H), 6.34 (d, *J* = 7.7 Hz, 1H), 5.63–5.56 (m, 2H), 5.06–4.96 (m, 3H), 4.79 (br s, 1H), 4.55 (dd, *J* = 11.3, 6.4 Hz, 1H), 3.81 (s, 3H), 3.61 (dd, *J* = 15.2, 5.9 Hz, 1H), 3.23 (s, 3H), 3.18–3.02 (m, 2H), 3.11 (s, 3H), 2.58 (s, 3H), 2.01 (dd, *J* = 14.9, 3.8 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 176.8, 171.1, 154.6, 154.1, 154.0, 149.4, 146.4, 138.3, 133.8, 132.4, 130.8, 129.9, 127.8, 125.9, 119.4, 118.4, 118.2, 116.4,

115.0, 113.7, 105.7, 71.1, 65.5, 56.7, 56.2 41.9, 37.5, 37.1, 30.1, 26.1, 24.9; HRMS-ES: $[M + Na]^+$ calcd for $C_{33}H_{34}N_2NaO_7$ 593.2264; found, 593.2274.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgment


We are grateful to the National Institutes of Health (CA-034303) for financial support of this research. We also thank Dr. H. Yennawar (Penn State Small Molecule X-Ray Crystallographic Facility) for the X-ray structure determinations, and Dr. Alan Benesi for assistance with 2D NMR experiments.

References


1. Numata A, Takahashi C, Ito Y, Takada T, Kawai K, Usami Y, Matsumura E, Imachi M, Ito T, Hasegawa T. *Tetrahedron Lett* 1993;34:2355.
2. Ratnayake AS, Yoshida WY, Mooberry SL, Hemscheidt TK. *J. Org. Chem* 2001;66:8717. [PubMed: 11749599]Ratnayake AS, Yoshida WY, Mooberry SL, Hemscheidt TK. *J. Org. Chem* 2003;68:1640. For the retraction of the nomofungin structure see:
3. (a) Jadulco R, Edrada RA, Ebel R, Berg A, Schaumann K, Wray V, Steube K, Proksch P. *J. Nat. Prod* 2004;67:78. [PubMed: 14738391] (b) Hayashi H, Matsumoto H, Akiyama K. *Biosci. Biotechnol. Biochem* 2004;68:753. [PubMed: 15056914] (c) Dalsgaard PW, Blunt JW, Munro MHG, Frisvad JC, Christophersen C. *J. Nat. Prod* 2005;68:258. [PubMed: 15730257]
4. Some structurally different compounds were initially designated as the same communesins due to simultaneous publication by two groups (see refs ^{3a} and ^{3b}). However, the current communesin nomenclature can be found in ref ^{3c}
5. Verbitski SM, Mayne CL, Davis RA, Concepcion GP, Ireland CM. *J. Org. Chem* 2002;67:7124. [PubMed: 12354007]Verotta L, Pilati T, Tato M, Elisabetsky E, Amador TA, Nunes DS. *J. Nat. Prod* 1998;61:392. [PubMed: 9548883]For another related alkaloid see:
6. Wigley LJ, Mantle PG, Perry DA. *Phytochemistry* 2006;67:561. [PubMed: 16324729]For recent labelling studies on the biosynthesis of the communesins see:
7. (a) May JA, Zeidan RK, Stoltz BM. *Tetrahedron Lett* 2003;44:1203. (b) May JA, Stoltz BM. *Tetrahedron* 2006;62:5262.
8. Yang J, Song H, Xiao X, Wang J, Qin Y. *Org. Lett* 2006;8:2187. [PubMed: 16671813]
9. Crawley SL, Funk RL. *Org. Lett* 2003;5:3169. [PubMed: 12943379]
10. Fuchs JR, Funk RL. *J. Am. Chem. Soc* 2004;126:5068. [PubMed: 15099080]
11. Sabahi A, Novikov A, Rainier JD. *Angew. Chem. Int. Ed* 2006;45:4317.
12. (a) Artman GD III, Weinreb SM. *Org. Lett* 2003;5:1523. [PubMed: 12713314]Artman, GD, III. The Pennsylvania State University; University Park, PA: 2004. Ph.D. Thesis
13. (a) Grigg R, Millington EL, Thornton-Pett M. *Tetrahedron Lett* 2002;43:2605. (b) Brown S, Clarkson S, Grigg R, Thomas WA, Sridharan V, Wilson DM. *Tetrahedron* 2001;57:1347. (c) Anwar U, Casaschi A, Grigg R, Sansano JM. *Tetrahedron* 2001;57:1361. (d) de Meijere A, Bräse S. *J. Organomet. Chem* 1999;576:88. (e) Poli G, Giambastiani G, Heumann A. *Tetrahedron* 2000;56:5959. (f) Negishi E, Ma S, Amanfu J, Copéret C, Miller JA, Tour JM. *J. Am. Chem. Soc* 1996;118:5919.
14. (a) Vetelino MG, Coe JW. *Tetrahedron Lett* 1994;35:219. (b) Coe JW, Vetelino MG, Bradlee M. *J. Tetrahedron Lett* 1996;37:6045.
15. Schumacher RW, Davidson BS. *Tetrahedron* 1999;55:935.
16. (a) Baldwin JE, Moloney MG, Parsons AF. *Tetrahedron* 1992;48:9373. (b) McCort G, Hoornaert C, Aletro M, Denys C, Duclos O, Cadilhac C, Guilpain E, Dellac G, Janiak P, Galzin A-M, Delahaye M, Guilbert F, O'Connor S. *Bioorg. Med. Chem* 2001;9:2129. [PubMed: 11504649]
17. Lipton MF, Basha A, Weinreb SM. *Org. Synth* 1979;59:49.
18. (a) Denmark SE, Schnute ME. *J. Org. Chem* 1995;60:1013. For some examples of reductive Heck reactions see: (b) Diaz P, Gendre F, Stella L, Charpentier B. *Tetrahedron* 1998;54:4579. (c) de Meijere

A, Meyer FE. *Angew. Chem. Int. Ed. Engl* 1994;33:2379. and references cited (d) Sajiki H, Ikawa T, Yamada H, Tsubouchi K, Hirota K. *Tetrahedron Lett* 2003;44:171. For a recent example of MeOH acting as a hydride transfer agent, see:

19. For preparation of lactones **16** and **31** see Supporting Information in ref ^{12a}
20. Levin JI, Turos E, Weinreb SM. *Synth. Commun* 1982;12:989.
21. (a) Seno K, Hagishita S, Sato T, Kuriyama KJ. *Chem. Soc. Perkin Trans* 1984;1:2013. (b) Ozlu Y, Cladingboel DE, Parsons P. J. *Tetrahedron* 1994;50:2183.
22. Prepared by reaction of Wittig reagent **2116** with known lactol **i** Mikami K, Ohmura H. *Org. Lett* 2002;4:3355. [PubMed: 12323017] to afford benzylidene lactone **ii**, which was then protected as shown:
23. Dai W-M, Lai KW. *Tetrahedron Lett* 2002;43:9377.
24. Tomioka K, Kawasaki H, Yasuda K, Koga K. *J. Am. Chem. Soc* 1988;110:3597. Similar facial selectivity controlled by the conformation of an α -substituent has been proposed for the alkylation of 6-membered lactone enolates:
25. Deslongchamps, P. *Stereoelectronic Effects in Organic Chemistry*. Pergamon; New York: 1983. p. 274-284.
26. Imming P, Imhof I, Zentgraf M. *Synth. Commun* 2001;31:3721.




- 1** R = R' = Me communesin A **5** R = Me communesin B
2 R = Me, R' = H communesin E **6** R = H communesin C
3 R = Et, R' = Me communesin G **7** R = CHO communesin D
4 R = Pr, R' = Me communesin H




9 "nomofungin"

10 perophoramidine


Figure 1.
Structures of the Communesins and Perophoramidine




Scheme 1.




Scheme 2.




Scheme 3.




Scheme 4.




Scheme 5.




Scheme 6.



Scheme 7.



Scheme 8.



Scheme 9.




Figure 2.
Models for Allylation of Lactones 16 and 29




Figure 3.
Transition State Models for Claisen Rearrangement of Ketene Acetals 46 and 58